Recent Quotes

My Watchlist

Indicators

(TSX: BCT )

0.9700 UNCHANGED

Streaming Delayed Price Updated: 3:47 PM EST, Nov 7, 2024 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	5,850
Open	0.9700
Bid (Size)	0.9700 (10)
Ask (Size)	1.010 (5)
Prev. Close	0.9700
Today's Range	0.9700 - 0.9900
52wk Range	0.6400 - 8.000
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Wave of FDA Fast Track Designations Highlight Biotech Momentum Carrying into 2023

September 13, 2023

FN Media Group Presents USA News Group News Commentary Vancouver, BC – September 13, 2023 – USA News Group – Sufferers of many different ailments saw reason to grow their hope in 2022 when the US Food...

Via FinancialNewsMedia

BriaCell Therapeutics Corp. CEO is Featured in an Interview With SmallCapsDaily

May 31, 2023

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Performance

YTD	-86.40%	-86.40%
1 Month	-34.46%	-34.46%
3 Month	+16.87%	+16.87%
6 Month	-68.61%	-68.61%
1 Year	-82.49%	-82.49%

More News

BriaCell Therapeutics Corp. CEO is Featured in an Interview With SmallCapsDaily

May 30, 2023

Via TheNewswire.com

BriaCell Therapeutics Corp. CEO is Featured in an Interview With SmallCapsDaily

May 30, 2023

Via NewMediaWire

Evolution of Oncology Treatments Giving New Hope to Those Diagnosed with Breast Cancer

March 24, 2023

Via FinancialNewsMedia

BriaCell’s Positive Clinical And Quality Of Life Data In Advanced Metastatic Breast Cancer Could Provide Hope For Patients

December 14, 2022

Via News Direct

BriaCell’s Positive Clinical And Quality Of Life Data In Advanced Metastatic Breast Cancer Could Provide Hope For Patients

December 14, 2022

Via TheNewswire.com

BriaCell’s Lead Candidate Bria-IMT™ Shows Promising Results For Advanced Breast Cancer Patients

December 02, 2022

Via TheNewswire.com

BriaCell’s Lead Candidate Bria-IMT™ Shows Promising Results For Advanced Breast Cancer Patients

December 02, 2022

Via News Direct

IPA’s Subsidiary BioStrand and BriaCell Announce Artificial Intelligence Collaboration and License Agreement to Discover and Develop Anti-Cancer Antibodies

November 30, 2022

From ImmunoPrecise Antibodies

Via Business Wire

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.